Woodcock Nostalgia: GOP Rep. Bilirakis Wants CDER To Recapture Her Flexible Approach

 
• By Derrick Gingery

Energy and Commerce Committee member suggests CBER now is more flexible with rare disease product approval requirements than CDER, inviting the drug center to return to its approach under former director Janet Woodcock.

Rep. Gus Bilirakis
Republicans called for more use of accelerated approval during an Energy and Commerce Committee hearing. • Source: Screenshot of House of Representatives broadcast

More from Rare Diseases

More from Pink Sheet